Shanghai Kaibao Pharmaceutical (300039) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Kaibao Pharmaceutical (300039) has a cash flow conversion efficiency ratio of 0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥190.98 Million ≈ $27.95 Million USD) by net assets (CN¥4.55 Billion ≈ $665.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Shanghai Kaibao Pharmaceutical net asset quality index to measure how much of total assets are equity-financed.
Shanghai Kaibao Pharmaceutical - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Shanghai Kaibao Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Shanghai Kaibao Pharmaceutical cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Shanghai Kaibao Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Kaibao Pharmaceutical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Empire State Realty Trust Inc
NYSE:ESRT
|
0.059x |
|
Seegene Inc
KQ:096530
|
0.037x |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
0.039x |
|
Lloyds Banking Group PLC
LSE:LLOY
|
0.141x |
|
Beijing New Space Technology Co Ltd
SHG:605178
|
0.001x |
|
Dynavox Group
ST:DYVOX
|
0.161x |
|
Navigator Global Investments Ltd
AU:NGI
|
0.054x |
|
Shanghai Prisemi Electronics Co Ltd
SHG:688230
|
0.012x |
Annual Cash Flow Conversion Efficiency for Shanghai Kaibao Pharmaceutical (2006–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Kaibao Pharmaceutical from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Shanghai Kaibao Pharmaceutical worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥4.10 Billion ≈ $600.40 Million |
CN¥278.95 Million ≈ $40.82 Million |
0.068x | -28.35% |
| 2023-12-31 | CN¥4.03 Billion ≈ $590.13 Million |
CN¥382.66 Million ≈ $56.00 Million |
0.095x | -5.19% |
| 2022-12-31 | CN¥3.76 Billion ≈ $550.36 Million |
CN¥376.42 Million ≈ $55.08 Million |
0.100x | +141.71% |
| 2021-12-31 | CN¥3.04 Billion ≈ $445.57 Million |
CN¥126.08 Million ≈ $18.45 Million |
0.041x | -57.41% |
| 2020-12-31 | CN¥2.58 Billion ≈ $377.29 Million |
CN¥250.65 Million ≈ $36.68 Million |
0.097x | -25.23% |
| 2019-12-31 | CN¥2.57 Billion ≈ $376.00 Million |
CN¥334.09 Million ≈ $48.89 Million |
0.130x | +23.16% |
| 2018-12-31 | CN¥2.49 Billion ≈ $363.65 Million |
CN¥262.36 Million ≈ $38.39 Million |
0.106x | +1.62% |
| 2017-12-31 | CN¥2.37 Billion ≈ $346.14 Million |
CN¥245.76 Million ≈ $35.96 Million |
0.104x | -27.40% |
| 2016-12-31 | CN¥2.20 Billion ≈ $321.97 Million |
CN¥314.88 Million ≈ $46.08 Million |
0.143x | -12.25% |
| 2015-12-31 | CN¥2.01 Billion ≈ $293.47 Million |
CN¥327.08 Million ≈ $47.86 Million |
0.163x | +8.85% |
| 2014-12-31 | CN¥1.88 Billion ≈ $275.78 Million |
CN¥282.38 Million ≈ $41.32 Million |
0.150x | -10.95% |
| 2013-12-31 | CN¥1.61 Billion ≈ $235.02 Million |
CN¥270.23 Million ≈ $39.54 Million |
0.168x | -1.89% |
| 2012-12-31 | CN¥1.42 Billion ≈ $207.61 Million |
CN¥243.32 Million ≈ $35.61 Million |
0.171x | +132.79% |
| 2011-12-31 | CN¥1.33 Billion ≈ $195.27 Million |
CN¥98.31 Million ≈ $14.39 Million |
0.074x | +360.54% |
| 2010-12-31 | CN¥1.24 Billion ≈ $181.01 Million |
CN¥19.79 Million ≈ $2.90 Million |
0.016x | -65.23% |
| 2009-12-31 | CN¥1.15 Billion ≈ $167.72 Million |
CN¥52.74 Million ≈ $7.72 Million |
0.046x | -68.76% |
| 2008-12-31 | CN¥126.92 Million ≈ $18.57 Million |
CN¥18.70 Million ≈ $2.74 Million |
0.147x | -51.29% |
| 2007-12-31 | CN¥76.96 Million ≈ $11.26 Million |
CN¥23.27 Million ≈ $3.41 Million |
0.302x | -42.84% |
| 2006-12-31 | CN¥37.24 Million ≈ $5.45 Million |
CN¥19.70 Million ≈ $2.88 Million |
0.529x | -- |
About Shanghai Kaibao Pharmaceutical
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more